Results 81 to 90 of about 5,736 (192)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

Journal of Cardiovascular Magnetic Resonance, 2008
Background In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur.
Pibiri Martina, Agus Annalisa, Westwood Mark A, Smith Gillian C, Dessi Carlo, Galanello Renzo, Tanner Mark A, Nair Sunil V, Walker J Malcolm, Pennell Dudley J   +9 more
doaj   +1 more source

Deferiprone for the treatment of Friedreich's ataxia.

, 2013
Friedreich's ataxia (FRDA) is a neurological disease related to a deficiency of the protein frataxin involved in iron-sulfur (Fe-S) cluster biogenesis.
Pandolfo, Massimo, Hausmann, Laura
core   +1 more source

Real‐world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron‐overloaded patients

British Journal of Haematology, Volume 208, Issue 6, Page 2320-2325, June 2026.
Barbara Gianesin, Antonietta Zappu, Giovanni Battista Ferrero, Carmen Maria Gaglioti, Michele Santodirocco, Giuseppe Fania, Giovanna Graziadei, Daniele Lello Panzieri, Antonella Massa, Tommaso Mina, Francesca Polese, Angelantonio Vitucci, Francesco Arcioni, Maria Caterina Putti, Valerio Cecinati, Ilaria Fotzi, Paola Maria Grazia Sanna, Antonio Cappello, Filomena Longo, Roberto Lisi, Annamaria Pasanisi, Daniela Pietrasanta, Monica Bocchia, Elisa Bertoni, Antonella Cossu, Marilena Serra, Susanna Barella, Antonia Gigante, Gian Luca Forni, Raffaella Origa   +29 more
wiley   +1 more source

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

PLoS ONE, 2016
UnlabelledAntiretrovirals suppress HIV-1 production yet spare the sites of HIV-1 production, the HIV-1 DNA-harboring cells that evade immune detection and enable viral resistance on-drug and viral rebound off-drug.
Deepti Saxena, Michael Spino, Fernando Tricta, John Connelly, Bernadette M Cracchiolo, Axel-Rainer Hanauske, Darlene D'Alliessi Gandolfi, Michael B Mathews, Jonathan Karn, Bart Holland, Myung Hee Park, Tsafi Pe'ery, Paul E Palumbo, Hartmut M Hanauske-Abel   +13 more
doaj   +1 more source

Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment. [PDF]

Sci Rep
Cisplatin-induced neurotoxicity is one of the limiting factors to its use especially in tumors that demand high drug dosage. One of the Cisplatin pathways is ferritinophagy which may end up in ferroptosis.
Seddiek H, Hanna M, Hamoud AEM, Elbaset MA, Akabawy AMA, Kotb MZ, Khalifa MM.   +6 more
europepmc   +2 more sources

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study

Journal of Cardiovascular Magnetic Resonance, 2009
Background Available iron chelation regimes in thalassaemia may achieve different changes in cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four available iron chelator regimes in 232 thalassaemia major ...
Berdoussi Eleni, Zannikos Kirykos, Moraitis Panagiotis, Chouliaras Giorgos, Berdoukas Vasilios, Ladis Vassilios   +5 more
doaj   +1 more source

The Evaiuation of chalator therapy in reducing serum ferritin and improving Ejection fraction (EF%) in thalassemic patients

Iranian South Medical Journal, 2015
Background: Thalassemic syndroms are the most common genetic disease in the world that related to blood transfusion and iron overload in the body. Cardiac complications are the leading cause of death in patients with thalassemia.
Saeadh Firouzbakhtkh, Khadejeh Ghasemi, Nilofar Motamed, Mahmoodreza Sarrikhani   +3 more
doaj  

Sex and Gender Differences in Iron Chelation

Biomedicines
Background/Objectives: In the absence of physiological mechanisms to excrete excessive iron, the administration of iron chelation therapy is necessary.
Sarah Allegra, Stefano Comità, Antonella Roetto, Silvia De Francia   +3 more
doaj   +1 more source

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

Drug Design, Development and Therapy, 2016
Christina N Kontoghiorghe, George J Kontoghiorghes Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus Abstract: The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East, and
Kontoghiorghe CN, Kontoghiorghes GJ
doaj  

The Oxidative Stress Response Highly Depends on Glucose and Iron Availability in Aspergillus fumigatus

Journal of Fungi
Pathogens have to cope with oxidative, iron- and carbon(glucose)-limitation stresses in the human body. To understand how combined iron–carbon limitation alters oxidative stress responses, Aspergillus fumigatus was cultured in glucose–peptone or peptone ...
Tamás Emri, Károly Antal, Kinga Varga, Barnabás Csaba Gila, István Pócsi   +4 more
doaj   +1 more source